60岁及以上高血压患者强化降压至临床获益所需时间:随机临床试验的二次分析
该二次分析纳入6项随机临床试验的27414例60岁及以上高血压患者,比较强化降压(收缩压目标<140 mmHg)与标准降压。强化降压与MACE风险降低21%显著相关(HR 0.79,95%CI 0.71-0.88,P<.001)。每500例患者预防1例MACE平均需9.1个月(95%CI 4.0-20.6),每200例和每100例分别需19.1个月和34.4个月。作者认为,预期寿命>3年的部分成人可能适合强化降压,而预期寿命<1年者可能不适合。
要点
- 60岁及以上高血压患者强化降压(收缩压目标<140 mmHg)与MACE风险降低21%显著相关(HR 0.79,95%CI 0.71-0.88,P<.001)。
- 每500例患者预防1例MACE平均需9.1个月(95%CI 4.0-20.6),绝对风险降低0.002。
- 每200例和每100例患者预防1例MACE分别需19.1个月(95%CI 10.9-34.2)和34.4个月(95%CI 22.7-59.8)。
- 作者认为,预期寿命>3年的部分60岁及以上高血压成人可能适合强化降压,预期寿命<1年者可能不适合。
适用人群与场景
- 60岁及以上高血压患者,来自6项以治疗达标为设计的随机临床试验,共27414例(平均年龄70岁,56.3%为女性)。
诊断标准与关键阈值
- 强化降压定义为收缩压目标<140 mmHg,对照为标准降压。
- MACE由各试验定义, broadly相似,均包括心肌梗死、卒中和心血管死亡。
研究设计与关键结果
- 二次分析纳入6项随机临床试验(2项原始数据、4项重建数据)共27414例60岁及以上高血压患者。
- 强化降压(收缩压目标<140 mmHg)与MACE风险降低21%显著相关(HR 0.79,95%CI 0.71-0.88,P<.001)。
- 每500例患者预防1例MACE平均需9.1个月(95%CI 4.0-20.6),绝对风险降低0.002。
- 每200例患者预防1例MACE需19.1个月(95%CI 10.9-34.2),绝对风险降低0.005。
- 每100例患者预防1例MACE需34.4个月(95%CI 22.7-59.8),绝对风险降低0.01。
证据类型、等级与局限
- 证据类型:随机临床试验的二次分析(个体患者数据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于60岁及以上高血压患者,强化降压可能适用于预期寿命>3年的部分成人,但可能不适用于预期寿命<1年者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Recent guidelines recommend a systolic blood pressure (BP) goal of less than 150 mm Hg or even 130 mm Hg for adults aged 60 years or older. However, harms from intensive BP treatments occur immediately (eg, syncope, fall), and benefits for cardiovascular event reduction emerge over time. Therefore, harms with low chance of benefit need to be clearer, particularly for those with limited life expectancy.
OBJECTIVE: To estimate the time needed to potentially derive clinical benefit from intensive BP treatment in patients 60 years and older.
DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis included individual patient data from published randomized clinical trials with 27 414 patients 60 years or older with hypertension. Patient-level survival data were reconstructed when the original data were not available. Published trials were identified by searching PubMed until October 15, 2021.
EXPOSURES: Intensive BP lowering vs standard BP lowering with the treat-to-target design.
MAIN OUTCOMES AND MEASURES: Major adverse cardiovascular event (MACE) defined by each trial, which was broadly similar with all trials including myocardial infarction, stroke, and cardiovascular mortality.
RESULTS: Six trials (original data from 2 trials and reconstructed data from 4 trials) with 27 414 participants (mean age, 70 years; 56.3% were women) were included in the analysis. Intensive BP treatment with a systolic BP target below 140 mm Hg was significantly associated with a 21% reduction in MACE (hazard ratio, 0.79; 95% CI, 0.71-0.88; P < .001). On average, 9.1 (95% CI, 4.0-20.6) months were needed to prevent 1 MACE per 500 patients with the intensive BP treatment (absolute risk reduction [ARR], 0.002). Likewise, 19.1 (95% CI, 10.9-34.2) and 34.4 (95% CI, 22.7-59.8) months were estimated to avoid 1 MACE per 200 (ARR, 0.005) and 100 (ARR, 0.01) patients, respectively.
CONCLUSIONS AND RELEVANCE: In this analysis, findings suggest that for patients 60 years and older with hypertension, intensive BP treatment may be appropriate for some adults with a life expectancy of greater than 3 years but may not be suitable for those with less than 1 year.
参考来源
- Chen T, Shao F, Chen K, et al. Time to Clinical Benefit of Intensive Blood Pressure Lowering in Patients 60 Years and Older With Hypertension: A Secondary Analysis of Randomized Clinical Trials. JAMA Intern Med. 2022. PMID: 35532917. doi:10.1001/jamainternmed.2022.1657
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。